LDL

Also found in: Medical, Acronyms, Encyclopedia, Wikipedia.

LDL

(ĕl′dē′ĕl′)
n.
A lipoprotein with a relatively high proportion of lipids and low proportion of protein that incorporates cholesterol and transports it to cells. High levels are associated with an increased risk of atherosclerosis and coronary artery disease. Also called LDL cholesterol.

[l(ow-)d(ensity) l(ipoprotein).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

LDL

abbreviation for
(Biochemistry) low-density lipoprotein
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

LDL

low-density lipoprotein: a plasma protein that is the major carrier of cholesterol in the blood, with high levels being associated with atherosclerosis.
[1975–80]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.LDL - a lipoprotein that transports cholesterol in the blood; composed of moderate amount of protein and a large amount of cholesterol; high levels are thought to be associated with increased risk of coronary heart disease and atherosclerosis
lipoprotein - a conjugated protein having a lipid component; the principal means for transporting lipids in the blood
LDL cholesterol - the cholesterol in low-density lipoproteins; the `bad' cholesterol; a high level in the blood is thought to be related to various pathogenic conditions
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Translations

LDL

abbr low density lipoprotein. V. lipoprotein.
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in
References in periodicals archive
Although the association between LDL subclasses and cardiovascular events are well known, there are limited data regarding the relationship between AIS subtypes and LDL subclasses in the literature (11).
The Further Cardiovascular outcomes Research with PCSK9 inhibition in subject with elevated risk (Fourier) trial was the pivotal efficacy and safety study for the proprotein convertase subtilisin- kexin type 9 (PCSK9) inhibitor evolocumb (Repatha) and enrolled patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of at least 70 mg/d.
However, the amount of cholesterol within a given lipoprotein is highly variable, but all atherogenic lipoproteins contain exactly one apoB; thus, apoB provides information regarding the number of LDL particles and the density of the molecule.
Your low-density lipoprotein (LDL, "bad") cholesterol is a key indicator of your cardiovascular risk.
Interestingly, most physicians prefer treating to an LDL goal and consider 70 mg/dl to be an appropriate target goal for people at the highest risk for cardiovascular disease [4].
The Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial was the pivotal efficacy and safety study for the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab (Repatha) and enrolled patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of at least 70 mg/dL (N Engl J Med.
Sabatine, of Brigham and Women's Hospital at Harvard Medical School in Boston, MA, and colleagues note that the clinical benefits of using statins to lower LDL cholesterol are widely accepted, largely due to the high-quality evidence of their safety and efficacy in clinical trials.
Antibodies against human lipoproteins were used to form antigen - antibody complexes with LDL (low density lipoproteins), VLDL (very low density lipoproteins) and Chylomicrons in a way that only HDL-cholesterol is selectively determined by an enzymatic cholesterol measurement.2,10
* Data demonstrating a more reliable measure of LDL quantity--LDL particle number (LDL-P)--that can identify statin-treated individuals with continued LDL-related ASCVD risk and guide therapy adjustment likely to result in additional reduction in ASCVD events
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.